Gold standard (test)

QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency

Retrieved on: 
Monday, August 15, 2022
Health, Infectious Diseases, Clinical Trials, Research, Pharmaceutical, Science, U.S. Securities and Exchange Commission, Â, Monkeypox, Union, Public health, Laboratory, World Health Organization, Budget, VZV, NYSE, Senior, HSV2, Growth, SEC, Research, Life, Government, Blood, European, DNA, COVID-19, Infection, Urinary tract infection, QIAGEN, List of life sciences, HH6, RNA, RUO, Gold standard (test), Herpes labialis, Enterovirus, Knowledge, WHO, World, Automation, QGEN, Meningitis, Protein, Monkeypox virus, Molecular diagnostics, PCR, Solution, LDT, HSV1, Vaccine, Pharmaceutical industry, Insight

The new panel currently for research use only (RUO) comes in cartridge form to run on QIAGENs QIAstat-Dx automated syndromic testing devices.

Key Points: 
  • The new panel currently for research use only (RUO) comes in cartridge form to run on QIAGENs QIAstat-Dx automated syndromic testing devices.
  • Currently the worlds only syndromic test for the pathogen, the panel will prove to be crucial for detecting and then combatting the spread of monkeypox around the globe.
  • The panels RUO-status means it currently can only be used for the surveillance not screening or diagnosing of monkeypox cases.
  • QIAGEN teams around the world are working with healthcare authorities to support testing for the monkeypox virus outbreak.

QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavirus variant B.1.1.529

Retrieved on: 
Friday, November 26, 2021
Health, Medical Devices, Infectious Diseases, Genetics, Other Health, Pharmaceutical, Biotechnology, Patient, QIAGEN, GISAID, Coronavirus, Protein, CE, NYSE, PCR, Beta, Romolo Manissero, Alpha, Severe acute respiratory syndrome coronavirus 2, Virus, Knowledge, Gold standard (test), SEC, B.1.1.7, Solution, Blood, Budget, Vaccine, COVID-19, Database, GenBank, U.S. Securities and Exchange Commission, DNA, Research, Gamma, Real-time, Infection, United Kingdom, Polymerase chain reaction, RNA, Molecular diagnostics, QGEN, Automation, Life, Growth, Animal, Computer data storage

QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against the genetic mutations of the variant, which is known by its scientific name, B.1.1.529.

Key Points: 
  • QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against the genetic mutations of the variant, which is known by its scientific name, B.1.1.529.
  • QIAGEN also offers the offers the QIAstat-Dx Respiratory+ test in the U.S., Europe and other markets for detection of more than 20 respiratory illnesses, including COVID-19 infections.
  • QIAGEN offers tests worldwide for use on this system for detection of the SARS-CoV-2 virus.
  • QIAGEN has been closely monitoring and will continue to do so the performance of its PCR tests as new variants emerge in the global fight against the coronavirus pandemic.